NCT04183283已完成1 期
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Oral Single-Doses of LY3526318 on Cinnamaldehyde-Induced Dermal Blood Flow in Healthy Females
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Decrease in Cinnamaldehyde (CA)-Induced Dermal Blood Flow (DBF) Relative to Placebo Measured by Laser Doppler Imaging (LDI) at 3 Hours Post-dose (LDI)
研究概览
简要总结
The main purpose of this study is to learn more about how LY3526318 affects blood flow to the skin in healthy women. For each participant, the study will last up to 28 days and Part B will last up to 78 days, including screening and follow-up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Must be healthy female participants as determined by medical history and physical examination
- •-Female participants must be nonpregnant and not lactating, or of nonchildbearing potential (either surgically sterilized [for example (e.g.) tubal occlusion, hysterectomy, bilateral salpingectomy] or physiologically incapable of becoming pregnant, or postmenopausal with amenorrhea for at least 12 consecutive months)
- •Must have a body-mass index of 18 to 30 kilograms per square meter, inclusive
- •Must be willing to follow specific study procedures including
- •No drugs (except study drug, hormonal contraceptives) 7 days prior to each assessment and until discharge from Clinical Research Unit (CRU)
- •No chocolate, alcohol, or caffeine containing products 24 hours prior to initiation of each assessment and until discharge
- •A complete 4 hour fast (water is allowed) prior to cinnamaldehyde (CA) assessment
- •Must have suitable skin characteristics for the dermal CA challenge procedures and measured through Laser Doppler Imaging (LDI)
排除标准
- •Must not be currently enrolled in or discontinued within the last 30 days or 5 half-lives of the study drug (whichever is longer), from a clinical study involving an investigational product or any type of medical research judged not compatible with this study
- •Must not have received treatment with biological agents (such as monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing
- •Must not have a history or presence of medical illness including, but not limited to, any cardiovascular, hepatic, respiratory, hematological, endocrine, psychiatric or neurological disease, convulsions, or any clinically significant laboratory abnormality that would preclude study participation
- •Must not have an abnormality in the 12-lead electrocardiogram (ECG) or confirmed Frederica's corrected QT interval greater than (>) 470 millisecond (msec)
- •Must not have a history of clinically significant multiple or severe drug allergies or severe post-treatment hypersensitivity reactions
- •Must avoid excessive tanning
- •Must not use lotions, oils, depilatory preparations, makeup, or other topical treatments on the arms on a regular basis or have used any topical treatments within 7 days prior to start of the first study day
- •Must not be a habitual and heavy consumer of coffee or caffeinated beverages (more than approximately 4 cups of tea, coffee, or cola drinks/day) or who cannot refrain from caffeinated beverages 24 hours prior to CA application
- •Must not be drinking alcohol 24 hours prior to each assessment
- •Must not be around second-hand smoke 24 hours prior to CA application or use nicotine-containing products. Ex-smokers should have ceased smoking at least 6 months
研究组 & 干预措施
Placebo
Placebo Comparator
Placebo administered orally in one of four study periods.
干预措施: Placebo (Drug)
LY3526318
Experimental
10 milligrams (mg), 30 mg and 100 mg LY3526318 administered orally in three of four study periods.
干预措施: LY3526318 (Drug)
结局指标
主要结局
Decrease in Cinnamaldehyde (CA)-Induced Dermal Blood Flow (DBF) Relative to Placebo Measured by Laser Doppler Imaging (LDI) at 3 Hours Post-dose (LDI)
时间窗: 3 hours post LY3526318 dose (pre-CA challenge), 3.3 hours post LY3526318 dose (post-CA challenge)
CA-induced DBF was measured by laser doppler imaging (LDI). Least Squares (LS) mean was determined by analysis of variance (ANOVA) model with treatment, period, sequence, time and treatment\*time interaction as fixed factors and subject within sequence as a random factor.
次要结局
- Plasma Concentrations of LY3526318 at 3 and 24 Hours(3 hours and 24 hours post dose)
- Decrease in CA-induced Dermal Blood Flow (DBF) Relative to Placebo Measured by Laser Speckle Contrast Imaging (LSCI) at 3 Hours Post-dose (LSCI)(3 hours post LY3526318 dose (pre-CA challenge), 3.3 hours post LY3526318 dose (post-CA challenge))
- Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3526318(Predose, 3 hours and 24 hours after each LY3526318 dose (days 1 through 50))
- PK: Maximum Observed Drug Concentration (Cmax) of LY3526318(Predose, 3 hours and 24 hours after each LY3526318 dose (days 1 through 50))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With OsteoarthritisOsteo Arthritis KneeOsteoarthritisNCT05080660Eli Lilly and Company160
已完成
2 期
Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic PainDiabetic Peripheral Neuropathic PainNCT05177094Eli Lilly and Company155
已完成
1 期
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or ObeseOverweightNCT06039826Eli Lilly and Company46
已完成
2 期
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic ArthritisArthritis, PsoriaticNCT02719171AbbVie185
已完成
3 期
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary AngioedemaHereditary Angioedema (HAE)NCT02584959Shire75